Business Description
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.
Business History
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -0.63
Total Equity: $18.42M
Shares: 30,289,072
Total Debt: $19.37M
Cash: $715,674
EBITDA: -$15.15M
Total Debt: $19.37M
Cash: $715,674
Revenue: $65.27M
Shares: 30,289,072
Revenue: $65.27M
Revenue: $65.27M
Revenue: $65.27M
Total Equity: $18.42M
Tax Rate: 0.0%
Equity: $18.42M
Total Debt: $19.37M
Cash: $715,674
Current Liabilities: $38.27M
Long-Term Debt: $5.85M
Total Debt: $19.37M
Total Equity: $18.42M
Shares: 30,289,072
Shares: 30,289,072
CapEx: -$55,675
Shares: 30,289,072
Stock Price: $0.24
Net Income: -$19.14M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jul 3, 2026 6:42am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $56.2M | $50.3M | $53.4M | $54.4M | $65.3M |
| Cost of Revenue | $47.9M | $44.4M | $49.0M | $50.1M | $57.4M |
| Gross Profit | $8.3M | $6.0M | $4.3M | $4.3M | $7.9M |
| Operating Expenses | $12.9M | $13.4M | $26.2M | $19.9M | $24.4M |
| Operating Income | -$4.5M | -$7.5M | -$21.8M | -$15.5M | -$16.5M |
| Net Income | -$8.0M | -$13.8M | -$18.5M | -$16.2M | -$19.1M |
| EBITDA | -$3.8M | -$8.9M | -$17.1M | -$13.9M | -$15.2M |
| EPS | $-23.74 | $-33.16 | $-2.15 | $-1.17 | $-0.63 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 3, 2026 6:42am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $286,487 | $20.7M | $3.8M | $315,105 | $715,674 |
| Total Current Assets | $39.8M | $56.0M | $36.6M | $25.5M | $38.4M |
| Total Assets | $49.4M | $68.0M | $66.0M | $54.3M | $65.5M |
| Current Liabilities | $29.9M | $21.7M | $24.3M | $25.8M | $38.3M |
| Long-Term Debt | $12.7M | $2.9M | $3.0M | $1.6M | $5.9M |
| Total Liabilities | $45.0M | $28.4M | $30.0M | $29.8M | $47.1M |
| Total Equity | $4.4M | $39.7M | $36.0M | $24.5M | $18.4M |
| Retained Earnings | -$34.3M | -$66.2M | -$91.6M | -$114.0M | -$133.2M |
Cash Flow (Annual)
Last updated: Jul 3, 2026 6:42am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$7.1M | -$14.9M | -$15.6M | -$7.7M | -$8.4M |
| Capital Expenditure | $-890,516 | $-383,073 | -$9.2M | $-418,075 | $-55,675 |
| Free Cash Flow | -$8.0M | -$15.3M | -$24.8M | -$8.1M | -$8.5M |
| Acquisitions (net) | $0 | $0 | -$5.2M | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $-376,863 | $0 | $-100,452 | $0 | $0 |
| Net Change in Cash | $-341,908 | $20.5M | -$16.9M | -$3.5M | $3.1M |
Analyst Estimates (Annual)
Last updated: Jul 3, 2026 6:42am (just now)| Metric | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Revenue |
$54.7M $54.7M – $54.7M
|
$64.4M $64.4M – $64.4M
|
$87.3M $87.3M – $87.3M
|
$110.8M $110.8M – $110.8M
|
| EBITDA |
-$11.5M -$11.5M – -$11.5M
|
-$13.6M -$13.6M – -$13.6M
|
-$18.4M -$18.4M – -$18.4M
|
-$23.3M -$23.3M – -$23.3M
|
| Net Income |
-$23.6M -$23.6M – -$23.6M
|
-$10.3M -$10.3M – -$10.3M
|
$302,890 $302,890 – $302,890
|
$2.1M $2.1M – $2.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 3, 2026 6:42am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -10.5% | +6.0% | +2.0% | +19.9% |
| Gross Profit Growth | -28.5% | -27.0% | -0.9% | +83.1% |
| Operating Income Growth | -64.9% | -192.1% | +28.8% | -6.4% |
| Net Income Growth | -73.7% | -34.1% | +12.7% | -18.3% |
| EBITDA Growth | -133.2% | -91.7% | +18.4% | -8.8% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-16 | Terzis Georgios | P-Purchase | 168,135.00 | $0.25 | $42,000 |
| 2026-06-11 | Siokas Grigorios | P-Purchase | 218,447.00 | $0.21 | $45,000 |
| 2026-06-10 | Siokas Grigorios | P-Purchase | 701,447.00 | $0.23 | $160,000 |
| 2026-05-19 | Karkantzos Theodoros Christos | A-Award | 20,000.00 | $0.28 | $5,660 |
| 2026-05-19 | Karkantzos Theodoros Christos | C-Conversion | 35,000.00 | $0.00 | $0 |
| 2026-05-19 | Hoidas John James | A-Award | 20,000.00 | $0.28 | $5,660 |
| 2026-05-19 | Hoidas John James | C-Conversion | 20,000.00 | $0.00 | $0 |
| 2026-05-19 | Demetriades Demetrios G. | A-Award | 20,000.00 | $0.28 | $5,660 |
| 2026-05-19 | Demetriades Demetrios G. | C-Conversion | 20,000.00 | $0.00 | $0 |
| 2026-05-19 | Aslidis Anastasios | A-Award | 40,000.00 | $0.28 | $11,320 |
| 2026-05-19 | Aslidis Anastasios | C-Conversion | 40,000.00 | $0.00 | $0 |
| 2026-05-19 | Bhutawala Suhel | A-Award | 20,000.00 | $0.28 | $5,660 |
| 2026-05-19 | Bhutawala Suhel | C-Conversion | 20,000.00 | $0.00 | $0 |
| 2026-05-19 | Terzis Georgios | A-Award | 850,000.00 | $0.28 | $240,550 |
| 2026-05-19 | Terzis Georgios | C-Conversion | 850,000.00 | $0.00 | $0 |
| 2026-05-19 | Siokas Grigorios | A-Award | 2,350,000.00 | $0.28 | $665,050 |
| 2026-05-19 | Siokas Grigorios | C-Conversion | 2,350,000.00 | $0.00 | $0 |
| 2025-12-31 | Siokas Grigorios | 0.00 | $0.00 | $0 | |
| 2025-12-31 | Terzis Georgios | 0.00 | $0.00 | $0 | |
| 2025-12-31 | Aslidis Anastasios | 0.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).